Livzon Pharmaceutical Group Secures Shareholder Approval for Key Resolutions

Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.

Livzon Pharmaceutical Group Inc. announced that during its Annual General Meeting for 2024 and the 2025 First Class Meetings of A and H Shareholders, all proposed resolutions were approved by shareholders. The meeting, held on May 29, 2025, saw significant shareholder participation, with Joincare and its associates abstaining from voting on one resolution due to a material interest. This approval of resolutions is likely to impact the company’s strategic direction and shareholder confidence positively.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$24.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is based in Zhuhai, Guangdong Province, China, and is involved in the manufacturing of a wide range of drugs and healthcare products.

Average Trading Volume: 1,156,094

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$32.44B

See more insights into 1513 stock on TipRanks’ Stock Analysis page.